RUI LU: Open Payments
NPI 1396512208 · PASADENA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,975 in 100 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $443 · 2025 $1,975
Food & beverage: $1,975
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 9 | $306 |
| ABBVIE INC. | 17 | $228 |
| Vanda Pharmaceuticals Inc. | 12 | $192 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $190 |
| Teva Pharmaceuticals USA, Inc. | 12 | $188 |
| Alkermes, Inc. | 8 | $182 |
| E.R. Squibb & Sons, L.L.C. | 4 | $182 |
| Lundbeck LLC | 9 | $153 |
| Neurocrine BioSciences, Inc. | 6 | $141 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
Products named: VRAYLAR, FANAPT, CAPLYTA, ARISTADA, COBENFY, REXULTI, INVEGA, INGREZZA.
Industry payments across TX — which companies pay providers there.
